Effect of sustained insulin-releasing device made of poly(ethylene glycol) dimethacrylates on retinal function in streptozotocin-induced diabetic rats
| Autor: | Ayako Hoshi, Remi Motoyama, Nobuhiro Nagai, Toshiaki Abe, Reiko Daigaku, Saaya Saijo, Hirokazu Kaji |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Blood Glucose
Male medicine.medical_specialty Materials science medicine.medical_treatment 0206 medical engineering Biomedical Engineering Biophysics Bioengineering 02 engineering and technology Hydrogel Polyethylene Glycol Dimethacrylate Retina Diabetes Mellitus Experimental Biomaterials Rats Sprague-Dawley Internal medicine medicine Electroretinography Animals Insulin Protein kinase C Diabetic Retinopathy Glial fibrillary acidic protein biology Capsule 021001 nanoscience & nanotechnology Streptozotocin 020601 biomedical engineering Rats Drug Liberation Endocrinology medicine.anatomical_structure Basal (medicine) Gene Expression Regulation biology.protein 0210 nano-technology Hybrid Renal Replacement Therapy Subcutaneous tissue medicine.drug |
| Zdroj: | Journal of materials science. Materials in medicine. 31(6) |
| ISSN: | 1573-4838 |
| Popis: | In this study, we developed a subcutaneous insulin-releasing device consisting of a disk-shaped capsule and drug formulation comprised of poly(ethylene glycol) dimethacrylates, then evaluated its efficacy on retinal function in streptozotocin (STZ)-induced diabetic rats. In vitro release studies showed that recombinant human insulin was released with a constant rate for more than 30 days. The device was able to maintain a basal level of blood glucose in diabetic rats for a prolonged period of more than 30 days, simultaneously preventing a decrease in body weight. For assessing the pharmacological effect of the device on retinal function in diabetic rats, electroretinograms were conducted for 12 weeks. The reduction in amplitude and delay in implicit time were attenuated by the device during the initial 4 weeks of application. The increase in gene expression of protein kinase C (PKC)-γ and caspase-3 in the diabetic retina was also attenuated by the device. Immunohistochemistry showed that the increase in glial fibrillary acidic protein expression in the diabetic retina was attenuated by the device. Histological evaluation of subcutaneous tissue around the device showed the biocompatibility of the device. In conclusion, the insulin-releasing device attenuated the reduction of retinal function in STZ-induced diabetic conditions for 4 weeks and the efficacy of the device might be partially related to PKC signaling in the retina. The long-term ability to control the blood glucose level might help to reduce the daily frequency of insulin injections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink